Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 5/20 | 0.40 |
| ▸ | TAF1 | P21675 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.38 |
| ▸ | STK4 | Q13043 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 5/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 2/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537776 | 0.87 | PLK1 (0.53) | BRD4PTK2IGF1RLRRK2PLK1 | |
| SCHEMBL3545085 | 0.80 | PDGFRB (0.51) | AURKAAURKBPLK1 | |
| SCHEMBL1185962 | 0.75 | IGF1R (0.49) | PTK2IGF1RAURKAPLK1MAPK7 | |
| SCHEMBL3538331 | 0.74 | MAPK7 (0.66) | BRD4PTK2IGF1RLRRK2PLK1 | |
| SCHEMBL1203210 | 0.74 | PLK1 (0.70) | BRD4PLK4PLK1RAD52BRDT | |
| SCHEMBL1203888 | 0.74 | RAD52 (0.57) | RPS6KA3BRD4PTK2IGF1RLRRK2 | |
| SCHEMBL3544724 | 0.74 | MAPK7 (0.51) | RPS6KA3BRD4PTK2IGF1RLRRK2 | |
| SCHEMBL1204277 | 0.74 | PLK1 (0.63) | BRD4PLK4PLK1RAD52BRDT | |
| SCHEMBL1202710 | 0.71 | STK4 (0.46) | BRD4TAF1PTK2AURKALRRK2 | |
| SCHEMBL12880145 | 0.70 | TNK2 (0.44) | RPS6KA3PTK2STK4PLK1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | RPS6KA3 248/4885BRD4 2662/4885TAF1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.